131 related articles for article (PubMed ID: 27499936)
1. Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer.
Badovinac S; Korsic M; Mursic D; Samarzija M; Cucevic B; Roglic M; Jakopovic M
J Thorac Dis; 2016 Jul; 8(7):1497-503. PubMed ID: 27499936
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
[TBL] [Abstract][Full Text] [Related]
3. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
4. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Topolcan O; Racek J; Minarik M; Benesova L; Bortlicek Z; Poprach A; Buchler T
Tumour Biol; 2015 Dec; 36(12):9215-22. PubMed ID: 26088452
[TBL] [Abstract][Full Text] [Related]
5. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.
Wilop S; Crysandt M; Bendel M; Mahnken AH; Osieka R; Jost E
Onkologie; 2008 Dec; 31(12):665-70. PubMed ID: 19060504
[TBL] [Abstract][Full Text] [Related]
6. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
[TBL] [Abstract][Full Text] [Related]
7. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer.
Jones JM; McGonigle NC; McAnespie M; Cran GW; Graham AN
Lung Cancer; 2006 Jul; 53(1):97-101. PubMed ID: 16698114
[TBL] [Abstract][Full Text] [Related]
8. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Riedl JM; Barth DA; Brueckl WM; Zeitler G; Foris V; Mollnar S; Stotz M; Rossmann CH; Terbuch A; Balic M; Niedrist T; Bertsch T; Stoeger H; Pichler M; Olschewski H; Absenger G; Ficker JH; Gerger A; Posch F
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824580
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
10. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy.
Mitsuyoshi T; Matsuo Y; Itou H; Shintani T; Iizuka Y; Kim YH; Mizowaki T
J Radiat Res; 2018 Jan; 59(1):50-57. PubMed ID: 29182777
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the Efficacy and Safety of Platinum Doublet Re-Challenge Chemotherapy in Patients with Recurrent Advanced Non-Small Cell Lung Cancer].
Mori A; Hirose T; Tamura A; Kusaka K; Matsui H; Ohta K
Gan To Kagaku Ryoho; 2016 Jun; 43(6):723-6. PubMed ID: 27306808
[TBL] [Abstract][Full Text] [Related]
13. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
15. [Predictive value of fibrinogen and high-sensitivity C-reaction protein for cardiovascular events in patients with stable coronary artery disease].
Huang W; Chen QW; Lei H; Deng W; Ke DZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Aug; 34(8):718-21. PubMed ID: 17081398
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
17. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?
Ozyurek BA; Ozdemirel TS; Ozden SB; Erdoğan Y; Ozmen O; Kaplan B; Kaplan T
Clin Respir J; 2018 Jun; 12(6):2013-2019. PubMed ID: 29356383
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
19. A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer.
Zeng Q; Xue N; Dai D; Xing S; He X; Li S; Du Y; Huang C; Li L; Liu W
J Cancer; 2017; 8(5):744-753. PubMed ID: 28382136
[No Abstract] [Full Text] [Related]
20. The role of inflammation in adjuvant chemotherapy-induced sarcopenia (Izmir Oncology Group (IZOG) study).
Oflazoglu U; Alacacioglu A; Varol U; Kucukzeybek Y; Salman T; Onal HT; Yilmaz HE; Yildiz Y; Taskaynatan H; Saray S; Butun O; Tarhan MO
Support Care Cancer; 2020 Aug; 28(8):3965-3977. PubMed ID: 32335732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
